Hanover Insurance
368 hedge funds and large institutions have $3.95B invested in Hanover Insurance in 2024 Q2 according to their latest regulatory filings, with 51 funds opening new positions, 133 increasing their positions, 127 reducing their positions, and 26 closing their positions.
96% more first-time investments, than exits
New positions opened: 51 | Existing positions closed: 26
6% more funds holding
Funds holding: 348 → 368 (+20)
5% more repeat investments, than reductions
Existing positions increased: 133 | Existing positions reduced: 127
0.04% less ownership
Funds ownership: 87.57% → 87.53% (-0.04%)
8% less capital invested
Capital invested by funds: $4.27B → $3.95B (-$324M)
Top Buyers
Top Sellers
| 1 |
Victory Capital Management
San Antonio,
Texas
|
-$21M |
| 2 |
Franklin Resources
San Mateo,
California
|
-$19.9M |
| 3 |
Principal Financial Group
Des Moines,
Iowa
|
-$19.9M |
| 4 |
SSA
Schonfeld Strategic Advisors
New York
|
-$19.6M |
| 5 |
Bank of New York Mellon
New York
|
-$15.3M |
THG Hedge Fund Activity: Q2 2024 in Review
368 of the 6,924 institutional investors tracked by Wall St. Rank reported a position in Hanover Insurance (THG) for Q2 2024, worth a combined $3.95B — down 7.6% from $4.27B a quarter earlier.
Buyers outnumbered sellers: 51 funds opened new THG positions and 26 closed out — a net gain of 25 holders — while 133 added to existing stakes and 127 trimmed.
The largest buyer was Balyasny Asset Management, adding an estimated $26.5M. The largest seller was Victory Capital Management, cutting an estimated $21M.
- 368 institutional investors held Hanover Insurance (THG) as of Q2 2024, up from 348 in Q1 2024.
- Funds reported $3.95B of Hanover Insurance stock for Q2 2024, down 7.6% quarter-over-quarter.
- 51 funds opened new Hanover Insurance positions in Q2 2024 and 26 closed out, a net change of +25 holders.
- The largest Hanover Insurance buyer in Q2 2024 was Balyasny Asset Management, an estimated $26.5M added.
- The largest Hanover Insurance seller in Q2 2024 was Victory Capital Management, an estimated $21M sold.
Based on aggregated 13F filings for Q2 2024.